



Press Release





Cipla announces Q1 FY1415 Unaudited Consolidated Financial Results

Mumbai, India, 14th Aug 2014: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its Unaudited Consolidated Financial Results for the quarter ended June 30, 2014 (Q1).

Key Financial & Performance Highlights Q1 FY1415 vis-a-vis Q1 FY1314:

(Current year figures include the relevant results of Cipla’s subsidiaries from the date they became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable).

- Net Sales grew by 13.6% to ₹2647 cr, up from ₹2331 cr
- Income from operations grew by 8.3% to ₹2720 cr, up from ₹2511 cr
- EBITDA at ₹542 cr, as against ₹690 cr for previous year which included certain large one-off items
- Profit after tax at ₹295 cr, as against ₹485 cr for previous year



Profit & Loss Highlights:

- Material cost is at 37.7% of income from operations in Q1 FY1415 as compared to 36.6% in Q1 FY1314.
- EBIDTA decreased by 21.4% and is at 19.9% of income from operations during Q1 FY1415.
- Profit after tax decreased by 39.3% to ₹295 cr during Q1 FY1415 as compared to ₹485 cr during Q1 FY1314.

Performance Review:

Domestic business:

- Domestic sales grew by 17% to ₹1289 cr during Q1 FY1415, up from ₹1102 cr during Q1 FY1314
- The growth in domestic sales was largely on account of growth in respiratory, anti-infective and cardiac therapies.

International business:

- Exports of formulations grew by 12.7% to ₹1218 cr during Q1 FY1415, up from ₹1081 cr during Q1 FY1314.
- Exports of APIs marginally declined to ₹140 cr during Q1 FY1415, from ₹148 cr during Q1 FY1314.
- The growth in export revenues was primarily due to growth in anti-retroviral, anti-asthma and anti-allergic segments

About Cipla:

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla's turnover in FY 14 was 1.67 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including USFDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard of quality both domestically and internationally.

Media Contacts:

Investor Relations

Anant Atal

Contact No.: 022 – 24826450

E-Mail: anant.atal@cipla.com

Corporate Communications

Jaisingh Balakrishnan

Contact No.: +91 9833836185

E Mail: jaisingh.krishnan@cipla.com